XNAS · Healthcare · Diagnostics & Research
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | 0.06 | 0.15 | +150.00% | $21.2M | ✅ Beat | +0.08% | -1.75% | — |
| 2026-05-07 | Q1 2026 | -0.52 | -0.45 | +13.46% | $301.7M | ✅ Beat | +2.96% | +6.94% | — |
| 2026-02-19 |
| Q4 2025 |
| -0.61 |
| -0.50 |
| +18.03% |
| $281.3M |
| ✅ Beat |
| +3.64% |
| -7.91% |
| -19.93% |
| 2025-10-29 | Q3 2025 | -0.61 | -0.39 | +36.07% | $265.2M | ✅ Beat | — | — | — |
| 2025-07-30 | Q2 2025 | -0.62 | -0.44 | +29.03% | $232.1M | ✅ Beat | -0.75% | -1.33% | +49.19% |
| 2025-04-30 | Q1 2025 | -0.59 | -0.49 | +16.95% | $203.5M | ✅ Beat | +3.47% | -15.86% | -14.00% |
| 2025-02-20 | Q4 2024 | -0.50 | -0.62 | -24.00% | $201.8M | ❌ Miss | -9.56% | -11.16% | -1.39% |
| 2024-11-06 | Q3 2024 | -0.74 | -0.45 | +39.19% | $191.5M | ✅ Beat | +13.05% | +24.99% | +45.79% |
Showing last 8 quarters.